A Prospective Study of Plasma Adiponectin and Pancreatic Cancer Risk in Five US Cohorts

Bao, Ying; Giovannucci, Edward; Kraft, Peter; Stampfer, Meir J.; Ogino, Shuji; Ma, Jing; Buring, Julie E.; Sesso, Howard D.; Lee, I-Min; Gaziano, J. Michael; Rifai, Nader; Pollak, Michael; Cochrane, Barbara B.; Kaklamani, Virginia; Lin, Jennifer; Manson, JoAnn E.; Fuchs, Charles S.; Wolpin, Brian M.

doi:10.1093/jnci/djs474

Cited by 105 publications

(99 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As a result, they suggested that low adiponectin levels could be associated with the development of pancreatic cancer in non-smokers (14). Similarly, in the study using 5 cohorts and published recently, 468 pancreatic cancer patients were compared to 1080 control patients and suggested that low adiponectin levels were associated with pancreatic cancer independent from gender, smoking and BMI (15). As seen, fi rst studies about this subject showed a direct relationship between high adiponectin and low leptin levels with pancreatic cancer, but with the inclusion of large cohort studies and increase in the number of cases, this relationship turned inversely, especially for adiponectin.…”

Section: Discussionmentioning

confidence: 91%

Roles of adiponectin and leptin as diagnostic markers in pancreatic cancer

Çolakoğlu¹,

Bostancı²,

Özdemi̇r³

et al. 2017

BLL

View full text Add to dashboard Cite

INTRODUCTION: Obesity is one of the most serious public health problem worldwide. Adipose tissue synthetize and secrete many growth factors and several cytokines known as adipokines. Studies demonstrated changes in the levels of these adipokines in many types of cancer associated with obesity. In this study, we aimed to evaluate the possible relationship between adiponectin and leptin levels with pancreas cancer and disease stage, representative of Turkish population. MATERIALS AND METHODS: The study was conducted between April 2012 -November 2013. Study included 46 patients -46 control subjects, who had pancreatic carcinoma. Results between the patients and the control group and relationship between the disease stage and results were evaluated.

show abstract

Section: Discussionmentioning

confidence: 91%

Roles of adiponectin and leptin as diagnostic markers in pancreatic cancer

Çolakoğlu¹,

Bostancı²,

Özdemi̇r³

et al. 2017

BLL

View full text Add to dashboard Cite

show abstract

“…Notably, circulating levels of adiponectin, an adipocyte-secreted hormone with insulin sensitizing and anti-inflammatory properties, has been revealed to be inversely correlated with pancreatic cancer risk, independent of other risk factors (25). Notably, meta-analyses of other anthropometric measures such as physical activity have primarily produced non-significant findings in relation to protective effects against pancreatic cancer (26)(27)(28) (28).…”

Section: Metabolic Syndrome and Pancreatic Cancer Riskmentioning

confidence: 99%

Statins and pancreatic cancer

et al. 2017

View full text Add to dashboard Cite

Abstract. Pancreatic cancer remains among the most lethal cancers, despite ongoing advances in treatment for all stages of the disease. Disease prevention represents another opportunity to improve patient outcome, with metabolic syndrome and its components, such as diabetes, obesity and dyslipidemia, having been recognized as modifiable risk factors for pancreatic cancer. In addition, statins have been shown to potentially reduce pancreatic cancer risk and to improve survival in patients with a combination of metabolic syndrome and pancreatic cancer. Furthermore, preclinical studies have demonstrated that statins exhibit antitumor effects in pancreatic cancer cell lines in vitro and animal models in vivo, in addition to delaying the progression of pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma (PDAC) and inhibiting PDAC formation in conditional K-Ras mutant mice. The mechanisms by which statins produce anticancer effects remain poorly understood, although appear to involve inhibition of the mevalonate/cholesterol synthesis pathway, thus blocking the synthesis of intermediates important for prenylation and activation of the Ras/mitogen-activated protein kinase 1 signaling pathway. Furthermore, statins have been identified to modulate the phosphoinositide 3-kinase/Akt serine/threonine kinase 1 and inflammation signaling pathways, and to alter the expression of genes involved in lipid metabolism, which are important for PDAC growth and proliferation. In addition, statins have been demonstrated to exhibit further antitumor mechanisms in a number of other cancer types, which are beyond the scope of the present review. In the present review, current evidence highlighting the potential of statins as chemopreventive agents in pancreatic cancer is presented, and the antitumor mechanisms of statins elucidated thus far in this disease are discussed.

show abstract

“…A low levels of serum adiponectin associated with the development of several cancers, including colon cancer (21)(22)(23). However, the mechanisms underlying the association between a decreased level of plasma adiponectin and carcinogenesis remains to be fully understood.…”

Section: A B C Dmentioning

confidence: 99%

Primary Intestinal Follicular Lymphoma and Premature Atherosclerosis in a Japanese Diabetic Patient with Atypical Familial Partial Lipodystrophy

Iwanishi¹,

Kusakabe

Washiyama³

et al. 2014

Intern. Med.

View full text Add to dashboard Cite

We experienced a case of primary intestinal follicular lymphoma and premature atherosclerosis in a diabetic patient with familial partial lipodystrophy (FPL) that was detected when the patient was evaluated for laparoscopic sleeve gastrectomy (LSG). As FPL is generally considered to be rare, FPL is often underdiagnosed, especially in obese patients. Therefore, the prevalence of FPL is higher than previous estimates. Our case illustrates that clinicians should perform screening for atherosclerosis and malignancy at the preoperative evaluation and may need to perform metabolic surgery earlier to prevent the development of excess truncal fat, complicated diabetes and atherosclerosis in patients with FPL.

show abstract

A Prospective Study of Plasma Adiponectin and Pancreatic Cancer Risk in Five US Cohorts

Cited by 105 publications

References 62 publications

Roles of adiponectin and leptin as diagnostic markers in pancreatic cancer

Roles of adiponectin and leptin as diagnostic markers in pancreatic cancer

Statins and pancreatic cancer

Primary Intestinal Follicular Lymphoma and Premature Atherosclerosis in a Japanese Diabetic Patient with Atypical Familial Partial Lipodystrophy

Contact Info

Product

Resources

About